When injected intravenously, stem cells naturally migrate to the lungs, exactly the area where therapy is needed in COVID-19 patients.
Each patient received two infusions of mesenchymal stem cells.
After an experiment that consisted of the infusion of stem cells derived from umbilical tissue in 24 patients with coronavirus, the experts responsible for the test reported through the journal STEM CELL Translational Medicine that they had good results, as the risk of death was reduced and the recovery period was shortened in the most serious cases of covid-19.
Camillo Ricordi, director of the Institute for Research and Diabetes and Cell Transplantation Center at the University of Miami, and an international team carried out the clinical trial authorized last April by the United States Food and Drug Administration (FDA, for its acronym in English).
The article describes the findings of the randomized trial of inpatients at Jackson Memorial Hospital with acute respiratory distress syndrome, a dangerous and often fatal complication evidenced by severe inflammation and fluid build-up in the lungs.
Each patient received two infusions of umbilical tissue derived mesenchymal stem cells (UC.MSC), or a placebo, administered several days apart. Neither the doctors nor the patients knew who received the treatment and who was given the placebo.
One month later, 100 percent of the patients who received the UC-MSC infusions survived compared to 42 percent in the control group, and the researchers determined that the therapy was safe with no serious side effects related to the disease. infusion.
Ricordi's team also noted that recovery was faster among the patients who received the treatment, and more than half of them were discharged from the hospital within two weeks.
More than 80 percent of the patients in the treatment group recovered 30 days later, compared with 37 percent in the control group.
"It's like a smart pump technology in the lungs to restore the normal immune response and reverse life-threatening complications," Rocordi said.
According to the article, an umbilical cord, donated after a cesarean section, is enough to obtain up to 10,000 doses of the treatment for covid-19. When injected intravenously, stem cells naturally migrate to the lungs, exactly the area where therapy is needed in COVID-19 patients.
"Our results confirm the powerful anti-inflammatory and immunity-modulating effect of UC-MSCs," said Giacomo Lanzoni, lead author of the paper. "These cells have clearly inhibited the 'cytokine storm (the overreaction of the body's immune system) that is typical of severe COVID-19," he added.
Ricordi's team included scientists from China and Israel who have been using the treatment with similar results, although neither of those studies have been randomized, which is a fundamental requirement in medical research.
-----
-------
RCG, Grupo Central Regenerativo
"By the most important Medical Community of Regenerative Medicine in Mexico"
Contact us: https://bit.ly/RCG_Boton
Comments